Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authorid0000-0003-0882-0524en_US
dc.contributor.authorBilici, Ahmet
dc.contributor.authorUysal, Mükremin
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorAkın, Semih
dc.contributor.authorYıldız, Fatih
dc.contributor.authorTuran, Merve
dc.contributor.authorKaplan, Muhammet Ali
dc.date.accessioned2023-01-20T08:18:57Z
dc.date.available2023-01-20T08:18:57Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.description.abstractPurpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.en_US
dc.identifier.citationBilici, A., Uysal, M., Menekşe, S., Akın, S., Yıldız, F., Turan, M. ve diğerleri. (2022). Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study. Cancer Investigation, 40(2), 199-209.en_US
dc.identifier.doi10.1080/07357907.2021.2017952
dc.identifier.endpage209en_US
dc.identifier.issn0735-7907
dc.identifier.issn1532-4192
dc.identifier.issue2en_US
dc.identifier.pmid34894960
dc.identifier.scopus2-s2.0-85121803055
dc.identifier.scopusqualityQ3
dc.identifier.startpage199en_US
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/07357907.2021.2017952
dc.identifier.urihttps://hdl.handle.net/11468/11210
dc.identifier.volume40en_US
dc.identifier.wosWOS:000734258300001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaplan, Muhammet Ali
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.ispartofCancer Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectEverolimusen_US
dc.subjectExemestaneen_US
dc.subjectMetastatic breast canceren_US
dc.subjectHormone receptor-positiveen_US
dc.subjectHER - negativeen_US
dc.subjectEfficacyen_US
dc.titleReal-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) studyen_US
dc.titleReal-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Real Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2.pdf
Boyut:
2.1 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu